NCT06484777 2026-04-16
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
Clinical Trials
137 trialsNCT07533123 2026-04-16
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Recruiting
NCT06788756 2026-04-13
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Moleculin Biotech, Inc.
Phase 2/3 Recruiting
NCT07326488 2026-04-13
A Study of MHB009C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Recruiting
NCT07192107 2026-04-09
A Study of MHB042C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Recruiting
NCT07192120 2026-04-09
A Study of MHB048C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Recruiting
NCT06431490 2026-04-08
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT07418749 2026-04-06
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT07296809 2026-04-02
SKB500 Combinations in Patients With Small Cell Lung Cancer
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 2 Recruiting
NCT07409428 2026-04-01
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 3 Recruiting
NCT07450976 2026-03-31
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT05020236 2026-03-27
MAGNETISMM-5
Pfizer
Phase 3 Recruiting
NCT07043725 2026-03-27
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT06482905 2026-03-24
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Tcelltech Inc.
Phase 1 Recruiting
NCT06897579 2026-03-23
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT07222969 2026-03-23
A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
Vibrant Sciences Limited
Phase 1/2 Recruiting
NCT07002034 2026-03-16
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Reunion Neuroscience Inc
Phase 2 Recruiting
NCT07111546 2026-03-11
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT06821503 2026-03-10
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT06765590 2026-03-09
Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase NA Recruiting
NCT07069062 2026-03-09
A Phase I/â…¡ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT07331155 2026-03-09
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT07042802 2026-03-06
A Phase Ib/â…¡ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT07230106 2026-03-03
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
NCT04752826 2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2 Recruiting
NCT06783647 2026-02-12
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT06956001 2026-02-12
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06970639 2026-02-12
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT07208149 2026-02-12
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Shenzhen Majory Biotechnology Co., Ltd.
Phase 1/2 Recruiting
NCT07281976 2026-02-12
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT06752811 2026-02-10
pompom
Shanghai Yizhong Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05620017 2026-02-09
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Bio-Thera Solutions
Phase 1 Recruiting
NCT07398339 2026-02-09
DVDMS
Shanghai Guangsheng Biopharmaceutical Co., Ltd
Phase 2 Recruiting
NCT06580301 2026-02-06
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
Excyte Biopharma Ltd
Phase 1/2 Recruiting
NCT07230405 2026-02-06
A Phase II Study of SKB571 in Patients With Lung Cancer
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 2 Recruiting
NCT06565689 2026-02-05
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
Excyte Biopharma Ltd
Phase 1 Recruiting
NCT06574568 2026-02-05
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Excyte Biopharma Ltd
Phase 1 Recruiting
NCT07196774 2026-01-30
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT06792552 2026-01-29
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NextCure, Inc.
Phase 1 Recruiting
NCT07229625 2026-01-28
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT07369505 2026-01-27
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
Phase 1 Recruiting
NCT07112222 2026-01-26
A Study of LM-350 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT07368478 2026-01-26
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies
Biocity Biopharmaceutics Co., Ltd.
Phase 1 Recruiting
NCT07348211 2026-01-23
SIM0610-101
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT07275242 2026-01-15
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT07110571 2026-01-09
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT06298058 2026-01-07
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
Shanghai Institute Of Biological Products
Phase 1 Recruiting
NCT05584800 2026-01-05
Study of ZGGS18 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT06883526 2026-01-05
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT06903377 2026-01-05
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting